MFIM
COGT icon

Mesirow Financial Investment Management’s Cogent Biosciences COGT Stock Holding History

Mesirow Financial Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,736
Closed -$99.6K – 555
2025
Q1 		$99.6K Hold
21,736
– – ﹤0.01% 564
2024
Q4 		$170K Buy
21,736
+241
+1% +$2.4K ﹤0.01% 561
2024
Q3 		$232K Buy
+21,495
New +$209K ﹤0.01% 520

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Mesirow Financial Investment Management's COGT Position: Q2 2025 in Review

Mesirow Financial Investment Management sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 21,736 shares — an estimated $99.6K sold.

Mesirow Financial Investment Management first reported a position in COGT in Q3 2024 and held it in 3 quarters. The position peaked at $232K in Q3 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Mesirow Financial Investment Management reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 21,736 Cogent Biosciences shares in Q2 2025, an estimated $99.6K.
  • Mesirow Financial Investment Management first reported a position in Cogent Biosciences in Q3 2024 and held it in 3 quarters.
  • Mesirow Financial Investment Management's Cogent Biosciences position peaked at $232K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2025, filed 4 Aug 2025.